" class="no-js "lang="en-US"> Kristof Vercruysse - Medtech Alert
Saturday, December 14, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Kristof Vercruysse

Kristof Vercruysse

About Kristof Vercruysse

Bringing numerous drugs from Lead identification/Proof of Concept in animals to Proof of Concept in Humans.
– Strategic and Executive management.
– Integrated Project Leadership and Development
– Alignment of Pharmacology, Manufacturing and Clinical Development
– Third Party Vendor Management
– Strong Medical input and KOL network in various therapeutic areas
– Orphan Drug Experience

Related Story

Fundraising

 TargED Biopharmaceuticals Raises EUR 39 Million in Series A Financing to Bring Groundbreaking Thrombolytic Treatment to Patients | Pharmtech Focus

TargED Biopharmaceuticals Raises EUR 39 Million in Series A Financing to Bring Groundbreaking Thrombolytic Treatment to Patients

February 22 2022

TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, […]